MorphoSys AG is one of the world's leading groups of biotechnology. Net sales break down by activity as follows:
- development of antibody for therapeutic applications in partnership with pharmaceutical and biotechnology companies (52.2%): for treating rheumatoid arthritis, cancers and infectious diseases;
- proprietary development of therapeutic antibodies and peptides (47.8%).
At the end of 2019, the MorphoSys AG held a portfolio of 28 products in clinical development including 5 in phase III, 13 in phase II and 10 in phase I, and 25 products in preclinical development phase.
Net sales break down geographically as follows: Germany (0.2%), Europe and Asia (54.8%) and North America (45%).